Pancreatic cancer drugs put to the test in early trial

NCT ID NCT04005690

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early phase trial is testing several targeted drugs in people with pancreatic cancer to see how they affect tumor biology. Researchers will compare tumor samples taken before and after treatment to understand which drugs might work best. The goal is not to treat the cancer directly, but to gather information that could guide future, more effective trials. About 90 participants with various stages of pancreatic cancer are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab
What this could lead to
If successful, this study could help design better, more personalized treatments for pancreatic cancer by showing which drugs affect tumor biology.
What could go wrong
This is a very early, small study focused on measuring drug effects in tumors, not on curing or treating the disease. Many drugs tested in early trials do not lead to approved treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • OHSU Knight Cancer Institute

    RECRUITING

    Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.